




# UCLA/Advarra Lunch and Learn Presentation and Discussion

# Initial Site Review Process



# Initial Submission Timelines



## Initial **Investigator/Site** Submission



- Advarra
- Site





## Common Needs for Site Clarification - Items That Can Add Time

- **Budget/Patient Compensation:**
  - Should be in place prior to CIRBI submission - cannot proceed with IRB review w/o information.
  - Compensation/stipend issues are major reason for IRB approval delay
- **Sites with ICF Edits:**
  - Minimize incorporating unique language into the study ICF template
  - Applies to sites with unique information (other than PI info on page 1, HIPAA/privacy, Injury, and Compensation Information)
  - Sponsor/CRO to provide site with WORD document of **most current** IRB Approved ICF Template for edits (only if needed)
  - If IRB makes additional ICF edits during review, redlines will be sent to Site for review **prior** to release
- **Follow-up Questions from Board Reviewer:**
  - IRB may Defer site application pending follow-up information
  - Will be communicated via Clarification process in CIRBI



# Status Requests and Escalations



## To Request Status Updates on Your Submission:

### First Action:

Contact your Advarra **Coordinator** listed in CIRBI using “*Contact IRB*” activity on the submission page



### Second Action:

Contact your Advarra **Coordinator** listed in CIRBI at the phone number listed in CIRBI

Aspirin Ltd. - 8675310 (DEMO PROTOCOL) (Pro00024918 - Multi-Site Protocol )	
Protocol Title:	Survey of individuals who have used aspirin for pain management
Expiry/Expiration Date:	3/27/2022
Review Interval:	12 Month
Related Protocol (if applicable):	
Company:	Advarra IRB
Advarra Client Services Coordinator:	Jay Smith (443-283-1526 / jay.smith@advarra.com)

### If Needed:

Contact **Client Success Partner** via e-mail or phone for additional support